Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
106535675 | 10653567 | 5 | F | 20140513 | 20160623 | 20141216 | 20160630 | EXP | US-THROMBOGENICS INC-CLI-2014-1057 | THROMBOGENICS | 80.32 | YR | F | Y | 0.00000 | 20160630 | MD | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
106535675 | 10653567 | 1 | PS | JETREA | OCRIPLASMIN | 1 | Intraocular | 0.125 MG, ONE TIME DOSE | 125422 | .125 | MG | SOLUTION FOR INJECTION | |||||||
106535675 | 10653567 | 2 | C | HYZAAR 50/125 | 2 | Oral | 1 TAB, QD | U | 0 | 1 | DF | ||||||||
106535675 | 10653567 | 3 | C | ZEBETA | BISOPROLOL FUMARATE | 1 | Oral | 5 MG, QD | U | 0 | 5 | MG | |||||||
106535675 | 10653567 | 4 | C | CALCIUM | CALCIUM | 1 | Oral | 1 TAB, QD | U | 0 | 1 | DF | |||||||
106535675 | 10653567 | 5 | C | VITAMIN D /00107901/ | ERGOCALCIFEROL | 1 | Oral | 1 TAB, QD | U | 0 | 1 | DF | |||||||
106535675 | 10653567 | 6 | C | ASPIRIN. | ASPIRIN | 1 | Oral | 81 MG, QD | U | 0 | 81 | MG | |||||||
106535675 | 10653567 | 7 | C | ADVAIR HFA | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | Respiratory (inhalation) | 1 PUFF, QD | U | 0 | |||||||||
106535675 | 10653567 | 8 | C | MIRAPEX | PRAMIPEXOLE DIHYDROCHLORIDE | 1 | Oral | 15 MG, QD | U | 0 | 15 | MG | |||||||
106535675 | 10653567 | 9 | C | FENOFIBRATE. | FENOFIBRATE | 1 | Oral | 134 MG, QD | U | 0 | 134 | MG | |||||||
106535675 | 10653567 | 10 | C | MELOXICAM. | MELOXICAM | 1 | Oral | 15 MG, QD | U | 0 | 15 | MG | |||||||
106535675 | 10653567 | 11 | C | TEMAZEPAM. | TEMAZEPAM | 1 | Oral | 15 MG, QD | U | 0 | 15 | MG | |||||||
106535675 | 10653567 | 12 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | 40 MG, QD | U | 0 | 40 | MG |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
106535675 | 10653567 | 1 | Vitreous adhesions |
106535675 | 10653567 | 2 | Hypertension |
106535675 | 10653567 | 3 | Hypertension |
106535675 | 10653567 | 4 | Medical diet |
106535675 | 10653567 | 5 | Medical diet |
106535675 | 10653567 | 6 | Cerebrovascular accident prophylaxis |
106535675 | 10653567 | 7 | Productive cough |
106535675 | 10653567 | 8 | Parkinson's disease |
106535675 | 10653567 | 9 | Hypercholesterolaemia |
106535675 | 10653567 | 10 | Osteoarthritis |
106535675 | 10653567 | 11 | Insomnia |
106535675 | 10653567 | 12 | Dyspepsia |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
106535675 | 10653567 | DS |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
106535675 | 10653567 | Chromatopsia | |
106535675 | 10653567 | Photopsia | |
106535675 | 10653567 | Pupillary reflex impaired | |
106535675 | 10653567 | Vision blurred | |
106535675 | 10653567 | Visual impairment | |
106535675 | 10653567 | Vitreous floaters |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
106535675 | 10653567 | 1 | 20140512 | 20140512 | 0 | |
106535675 | 10653567 | 2 | 2007 | 0 | ||
106535675 | 10653567 | 3 | 2007 | 0 | ||
106535675 | 10653567 | 4 | 2013 | 0 | ||
106535675 | 10653567 | 5 | 2007 | 0 | ||
106535675 | 10653567 | 6 | 2013 | 0 | ||
106535675 | 10653567 | 7 | 2010 | 0 | ||
106535675 | 10653567 | 8 | 2009 | 0 | ||
106535675 | 10653567 | 9 | 2004 | 0 | ||
106535675 | 10653567 | 10 | 2012 | 0 | ||
106535675 | 10653567 | 11 | 1999 | 0 | ||
106535675 | 10653567 | 12 | 2012 | 0 |